Stifel Financial Corp Buys 2,174 Shares of Iradimed Corporation (NASDAQ:IRMD)

Stifel Financial Corp lifted its position in Iradimed Corporation (NASDAQ:IRMD) by 9.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 24,428 shares of the medical equipment provider’s stock after purchasing an additional 2,174 shares during the period. Stifel Financial Corp’s holdings in Iradimed were worth $1,229,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Huntington National Bank lifted its holdings in shares of Iradimed by 51.3% in the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock worth $75,000 after buying an additional 504 shares during the period. Gladius Capital Management LP grew its holdings in Iradimed by 126.6% during the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 965 shares in the last quarter. Quantbot Technologies LP increased its position in Iradimed by 83.0% during the 3rd quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 1,052 shares during the period. SG Americas Securities LLC bought a new stake in shares of Iradimed in the 3rd quarter valued at about $147,000. Finally, Bailard Inc. bought a new position in shares of Iradimed during the second quarter valued at approximately $202,000. Institutional investors own 92.34% of the company’s stock.

Iradimed Stock Up 2.4 %

Shares of NASDAQ:IRMD opened at $54.65 on Monday. The firm has a 50 day moving average of $52.97 and a 200 day moving average of $48.37. The company has a market capitalization of $692.58 million, a price-to-earnings ratio of 37.43 and a beta of 0.82. Iradimed Corporation has a 52 week low of $40.18 and a 52 week high of $57.95.

Iradimed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.10%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed’s dividend payout ratio (DPR) is currently 41.10%.

Insider Activity at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now directly owns 4,383 shares in the company, valued at $237,470.94. This trade represents a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 37.10% of the stock is owned by corporate insiders.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.